Université Grenoble Alpes, CNRS, CEA, IBS , Grenoble, France.
J Virol. 2023 Nov 30;97(11):e0091023. doi: 10.1128/jvi.00910-23. Epub 2023 Nov 3.
The main limitation of oncolytic vectors is neutralization by blood components, which prevents intratumoral administration to patients. Enadenotucirev, a chimeric HAdV-11p/HAdV-3 adenovirus identified by bio-selection, is a low seroprevalence vector active against a broad range of human carcinoma cell lines. At this stage, there's still some uncertainty about tropism and primary receptor utilization by HAdV-11. However, this information is very important, as it has a direct influence on the effectiveness of HAdV-11-based vectors. The aim of this work is to determine which of the two receptors, DSG2 and CD46, is involved in the attachment of the virus to the host, and what role they play in the early stages of infection.
溶瘤病毒载体的主要局限性是被血液成分中和，这阻止了其在肿瘤内给予患者。通过生物选择鉴定的嵌合 HAdV-11p/HAdV-3 腺病毒 Enadenotucirev 是一种低血清流行率的载体，对广泛的人类癌细胞系具有活性。在现阶段，关于 HAdV-11 的趋向性和主要受体利用仍存在一些不确定性。然而，这些信息非常重要，因为它直接影响基于 HAdV-11 的载体的有效性。本工作的目的是确定在病毒附着到宿主时涉及的两种受体，即 DSG2 和 CD46，以及它们在感染的早期阶段所起的作用。
